DaVita HealthCare (DVA) Increased by 13% Since Last Earnings Report: Will Growth Persist?

DaVita HealthCare (DVA) has seen a notable 13% increase since its last earnings report. This performance has outpaced the S&P 500, prompting investors to question whether this upward trend will be sustained till the next earnings release or if a reversal is on the horizon. Understanding the recent financial results and market reactions can offer valuable insights into the current trajectory of DaVita Inc.

In the fourth quarter of 2025, DaVita reported adjusted earnings per share of $3.40 from continuing operations, marking a substantial 51.8% increase from the previous year. This figure exceeded analyst expectations by 5.1%. On a GAAP basis, earnings per share dropped by 4.9% year over year to $2.94 for the quarter. The full-year adjusted earnings per share stood at $10.78, reflecting an 11.4% growth compared to the previous year and beating the consensus estimate by 0.7%.

Revenue figures for DaVita in the fourth quarter reached $3.62 billion, reflecting a 9.9% yearly increase and surpassing expectations by 2.7%. The dialysis patient service revenues accounted for $3.39 billion, up by 8.9% from the previous year. Additionally, other revenues amounted to $220.6 million, showing a robust increase of 25.7% compared to the same quarter in the previous year.

In terms of dialysis treatments, during the fourth quarter of 2025, DaVita conducted 7,264,520 U.S. dialysis treatments, averaging 91,608 per day. This represents a marginal daily decline of 0.1% from the previous quarter. On a normalized basis, non-acquired treatments fell by 0.6% year over year in the same quarter. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers globally.

Regarding DaVita’s financial position, the company closed the fourth quarter with $700.7 million in cash and cash equivalents and short-term investments. Its total debt stood at $10.27 billion during the same period. Cash flow provided by operating activities reached $1.89 billion, down from $2.02 billion in the previous year. DaVita repurchased 2.7 million shares for $331 million during the last quarter of 2025, indicating confidence in its market position.

DaVita’s performance in the recent quarter has shown positive momentum, reflected in its financial results and market reactions. With consistent growth in revenues and earnings, alongside strategic investments and acquisitions, DaVita continues to strengthen its market presence and drive shareholder value. The company’s focus on developing integrated care arrangements and expanding its global footprint underscores its commitment to innovation and growth in the healthcare sector. Investors are keenly observing DaVita’s trajectory and eagerly await its upcoming earnings report to gauge future performance.